Wolfe Research Warns: Corcept Stock Pricing in Too Many Perfect Outcomes
Corcept stock looks overpriced despite strong drug sales; analysts warn expectations are too high and risks could drag shares lower.
/ 10 items
#CORT↓
FDA Review Back on Track – Corcept Resubmits Relacorilant for Cushing’s Treatment
Corcept will resubmit its NDA for relacorilant to treat Cushing’s syndrome after positive FDA feedback.
UBS Turns Bullish on CORT: Lifyorli Expected to Beat Expectations
UBS upgraded CORT to Buy, raised target to $72 on strong Lifyorli cancer drug outlook and steady Korlym sales. Upside ~60–70%.
FDA Greenlights Relacorilant + Nab-Paclitaxel for Hard-to-Treat Ovarian Cancer
The FDA has approved Corcept's relacorilant (Lifyorli) in combination with nab-paclitaxel for platinum-resistant ovarian, fallopian tube, or peritoneal cancer, showing improved survival by several months.
Corcept Director Drops $3.35 Million on 100,000 Shares – Strong Insider Buy Signal
Corcept Therapeutics director Leonard Baker Jr. purchased 100,000 common shares at ~$33 each in open-market buys.
Corcept Therapeutics Stock Drops After Losing Patent Appeal to Teva
Corcept Therapeutics shares fell sharply to $29.71 in morning trading, following a Federal Circuit ruling affirming no patent infringement by Teva's generic version of Korlym.